2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan

Background

Chemotherapy-induced nausea and vomiting (CINV) occurs in two arbitrarily defined phases: the acute phase (from 0 to 24 h following chemotherapy (CT) initiation) and the delayed phase (from 24 to 120 h). Almost all antiemetic studies have therefore evaluated efficacy to 120 h after the administration of CT, and the period beyond 120 h is generally perceived to be relatively free of CINV, with some studies reporting continued nausea beyond the delayed phase.

Methods

In July and September of 2022, healthcare providers (HCPs) in Japan were recruited to complete an online quantitative survey. All HCPs were required to work with patients receiving anticancer CT in the hospital setting and have experience selecting, preparing and/or administering antiemetics. As part of this survey responses were collected on whether HCPs had patients who experienced nausea/vomiting (CINV) during Days 5-7 (beyond the delayed phase) after initiation of CT. Responses were also captured by CT regimen; for the physician subset, respondents were grouped by and analyzed only if they were prescribers of the chemotherapy type.

Results

A total of 809 HCPs (174 pharmacists, 102 nurses and 533 physicians) completed the survey. The physician group was comprised of breast surgeons (n = 57), pulmonologists (n = 107), gastroenterologists (n = 74), GI surgeons (89), gynecologists (n = 98), ENTs (n = 54), and oncologists (n = 54). The vast majority of respondents (98%, 93%, and 88% of pharmacists, nurses, and physicians, respectively) indicated they had patients who experienced CINV 5-7 days after CT. Of the HCPs reporting patients with CINV on Days 5-7, the highest proportions were seen for cisplatin, AC and EC chemotherapy regimens (Table). Table: 2078P

Proportions of respondents with patients experiencing CINV on days 5-7 by chemotherapy regimen

Conclusions

This survey highlights a need for continued assessment of CINV beyond the delayed phase after CT to better understand the incidence and to optimize prevention of CINV for the entire period of risk.

Clinical trial identification

Editorial acknowledgement

Jennifer Vanden Burgt.

Legal entity responsible for the study

Helsinn Healthcare.

Funding

Helsinn Healthcare.

Disclosure

F. Scotté: Financial Interests, Personal, Advisory Board: Helsinn Healthcare, Vifor, MSD, Tesaro; Financial Interests, Personal, Financially compensated role: Roche, Amgen, Pfizer, Leo Pharma, Viatris, Mundi Pharma, Clovis Oncology, BMS, Biogaran, Pierre Fabre Oncology, Arrow, GSK. M.S. Aapro: Financial Interests, Personal, Invited Speaker: Amgen, ViforPharma; Financial Interests, Institutional, Other, Grant to SPCC: BMS, ExactSciences, Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Institutional, Invited Speaker, Grant to SPCC: Helsinn; Financial Interests, Institutional, Other, grant to SPCC: Mundipharma, Fresenius Kabi, Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Member of Board of Directors: European Cancer Organisation, SIOG, UICC; Financial Interests, Institutional, Member of Board of Directors: SPCC, ALL CAN; Non-Financial Interests, Advisory Role, Confidentiality agreement: Various companies; Non-Financial Interests, Leadership Role: European Cancer Organisation, SPCC, SIOG; Non-Financial Interests, Member: MASCC, SBOC, ASCO; Other, SAB member: European School of Oncology. Y. Takeuchi: Financial Interests, Personal, Full or part-time Employment: Intage Healthcare Inc. All other authors have declared no conflicts of interest.